New Biosensor Visualizes Stress in Living Plant Cells in Real Time – Newswise

Newswise Plant biologists have long sought a deeper understanding of foundational processes involving kinases, enzymes that catalyze key biological activities in proteins. Analyzing the processes underlying kinases in plants takes on greater urgency in todays environment increasingly altered by climate warming.

Certain SnRK2 kinases (sucrose-non-fermenting-1-related protein kinase-2s) are essential since they are known to be activated in response to drought conditions, triggering the protective closure of small pores on leaf surfaces known as stoma. These pores allow carbon dioxide to enter leaves, but plants also lose more than 90 percent of their water by evaporation through them. Pore opening and closing functions help optimize growth and drought tolerance in response to changes in the environment.

Now, plant biologists at the University of California San Diego have developed a new nanosensor that allows researchers to monitor SnRK2 protein kinase activity in live plant cells. The SnRK2 activity sensor, or SNACS, is described in the journal eLife.

Prior efforts to dissect protein kinase activities involved a tedious process of grinding up plant tissues and measuring kinase activities through cell extracts. More than 100 leaves were required per experiment for analyses of the stomatal pore forming guard cells. SNACS now allows researchers to analyze changes in real time as they happen.

Previously, it was not possible to investigate time-resolved SnRK2 activity in living plant cells, said Biological Sciences Distinguished Professor Julian Schroeder, a member of the Section of Cell and Developmental Biology and senior author of the new paper. The SNACS sensor reports direct real-time visualization of SnRK2 kinase activity in single live plant cells or tissues.

The new biosensor is already paying dividends. The researchers describe using SNACS to provide new evidence about longstanding questions about SnRK2 and foundational interactions with carbon dioxide. The researchers show that abscisic acid, a drought stress hormone in plants, activates the kinases, but that elevated carbon dioxide does not, resolving a recently debated question.

Our findings could benefit researchers investigating environmental stress responses in plants and analyzing how different signaling pathways interact with one another in plant cells, said Yohei Takahashi, a UC San Diego project scientist and co-corresponding author of the study. The ability to investigate time-resolved SnRK2 kinase regulation in live plants is of particular importance for understanding environmental stress responses of plant cells.

The new nanosensor was developed using an approach pioneered by the late UC San Diego Professor Roger Tsien, in part for which he was awarded a Nobel Prize.

The research team included Li Zhang, Yohei Takahashi, Po-Kai Hsu, Kollist Hannes, Ebe Merilo, Patrick Krysan and Julian Schroeder.

Funding for the research was provided by the National Institutes of Health (GM060396), the National Science Foundation (MCB-1900567 and MCB-1137950), a China Scholarship Council fellowship and a Postdoctoral Fellowship for Research Abroad from the Japan Society for the Promotion of Science.

Originally posted here:
New Biosensor Visualizes Stress in Living Plant Cells in Real Time - Newswise

What are Proteoforms (Protein Variation)? – News-Medical.net

Protein variation, which accounts for large amounts of the complexity in biological systems and our bodies, can come in many different forms. The different types of variation, namely variations in the molecular form of protein products, are united by the term proteoform (previously also known as protein forms, protein isoforms, protein species, and protein variants).

Image Credits: StudioMolekuul / Shutterstock.com

Endeavors into understanding genetic variation led to the discovery that much of the variation and complexity in biology is due to proteins, rather than only genes. Different proteoforms can arise due to genetic variation, manipulation or splicing of RNA transcripts, and modifications occurring after translation.

There are a few exceptions to protein variations that are not covered by the term proteoforms. These include post-translational modifications that are known as reagent-derivatized or isotope-labeled residues. Otherwise, proteoforms are used to understand the full complexity of proteins and how the different sources of variation can interact to give rise to differences.

Genetic variation giving rise to proteoforms can largely be attributed to coding single nucleotide polymorphisms (cSNPs) and mutations. Variation at the RNA level can be mainly attributed to alternative splicing.

For example, it is estimated that around 93% of human genes are subject to alternative splicing. These can have implications for function and localization. Variation at the RNA level can also be due to RNA editing, with the most common editing being where adenosine is edited to inosine.

Translation is not a perfect process, and errors in translation are another source by which unique proteoforms can arise. Estimated error frequencies are at around 0.01-0.1% per amino acid, which may increase in aging or stressed cells, meaning errors can make up a sizable portion of variation in cells with many proteins.

Post-translational modifications are also a sizable source of proteoforms, as they can increase proteoform numbers exponentially. Post-translational modifications can be divided into categories based on structure or function.

For example, structural categories can look at if modifications are simple (e.g. phosphor or acetyl) or complex (e.g. glycosylation) and how this increases proteoform numbers. Functional categories focus on the effects of post-translational modifications on phenotypes, thereby focusing on how proteoforms can give rise to different forms.

The size of the proteome is subject to a lot of debate, with values ranging from 20,000 to several million. While the human genome can be estimated to be around 20,000 protein-coding genes, the size of the proteome can be several magnitudes larger due to the great variation of proteoforms.

The presence and function of proteoforms can be critical for normal body functioning. In humans, there are 23 known proteoforms in the amyloid- system in Alzheimers disease, where the different proteoforms are not detectable through traditional ELISA assays. There are also around 75 known proteoforms for the histone H4 system, which is associated with gene repression and activation.

Understanding the full extent of the human proteoform will be challenging. Not only is it necessary to understand how many proteoforms exist, but the way proteoform diversity varies between cell types, their role in disease, and their role in human diversity will be complex and difficult to decipher. Projects such as the Human Protein Atlas and the Human Cell Atlas have been launched in the past 10 years to help understand human diversity, and will likely include proteoforms.

While proteomics platforms have been massively improved in recent decades, there are still discrepancies in proteoform detection. For example, alternative transcripts that are discovered via RNA sequencing are not always found using proteomics methods.

The low detection of proteoforms of this type is due to limited sensitivity and coverage of the currently used proteomics platforms. Even methods where most gene expression can be detected, called deep proteomic analyses, the sequence coverage for many proteins is low. This is especially true for low abundance genes.

Another complication to detecting proteoforms is that they cannot be detected by the currently dominant strategy. The bottom-up approach most widely used involves digestion of proteins to detect peptides with LC-MS/MS, but most proteoforms share peptides with each other and thus this method is often inappropriate. The top-down approach is often seen as better, where proteins are not digested and instead the entire proteoform is analyzed by LC-MS/MS.

Read the rest here:
What are Proteoforms (Protein Variation)? - News-Medical.net

Human Embryonic Stem Cell Market to Witness a Ravishing Growth with International Players BD, Takara Bio Inc., Geron, Thermo Fisher Scientific Inc.,…

The Human Embryonic Stem Cell Market research added by the insight partners, offers a comprehensive analysis of growth trends prevailing in the global business domain. This report also provides definitive data concerning market, size, commercialization aspects and revenue forecast of the industry. In addition, the study explicitly highlights the competitive status of key players within the projection timeline while focusing on their portfolio and regional expansion endeavors.

What is Human Embryonic Stem Cell?

The human embryonic stem cells are obtained from the undifferentiated inner mass cell of the human embryo and human fetal tissue. The human embryonic stem cell can replicate indefinitely and produce non-regenerative tissue such as myocardial and neural cells. This potential of human embryonic stem cell allows them to provide an unlimited amount of tissue for transplantation therapies to treat a wide range of degenerative diseases. Hence, human embryonic stem cells are used in the treatment of various diseases such as Alzheimers disease, cancer, blood and genetic disorders related to the immune system and others.

Get Sample PDF Of Human Embryonic Stem Cell Market @https://www.theinsightpartners.com/sample/TIPRE00005165/

Major Players Included in this report are as follows:1. BD2. Takara Bio Inc.3. Geron4. Thermo Fisher Scientific Inc.5. ViaCyte, Inc.6. R&D Systems, Inc.7. QIAGEN8. CellGenix GmbH9. Vitrolife10. Lonza

The global human embryonic stem cell market is expected to grow in upcoming years, factors driving the growth of market are rise in incidences of neurological disorders, increase in investment by government and other organization for research activities, awareness among people about stem cell therapeutic potency for disease treatment. On the other hand emerging stem cell banking services is expected to offer lucrative opportunities in growth of human embryonic stem cell market.

Segmentation Analysis:

The global human embryonic stem cell market is segmented on the basis of product type, application and end user. Based on product type, the market is segmented as totipotent stem cell, pluripotent stem cell and unipotent stem cell. On the basis of application, the global human embryonic stem cell market is segmented into regenerative medicine, stem cell biology research, tissue engineering and toxicology testing. Based on end users, the market is segmented as therapeutics companies, cell & tissue banks, tools & reagents companies and others.

Human Embryonic Stem Cell Market: Regional analysis includes:

o Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)o Europe(Turkey, Germany, Russia UK, Italy, France, etc.)o North America(the United States, Mexico, and Canada.)o South America(Brazil etc.)o The Middle East and Africa(GCC Countries and Egypt.)

Human Embryonic Stem Cell Market: Competitive Landscape-

Analysts have thoroughly evaluated the competitive landscape in the Human Embryonic Stem Cell Market. The report includes the study of key players in the Human Embryonic Stem Cell Market. It also outlines the strategic initiatives companies have taken in recent years to keep pace with increasing competition. It also includes an assessment of the financial perspectives of these companies, their research and development plans, and their future business strategies.

Chapter Details of Human Embryonic Stem Cell Market:

1. Introduction2. Human Embryonic Stem Cell Market Key Takeaways3. Research Methodology4. Human Embryonic Stem Cell- Market Landscape5. Global Human Embryonic Stem Cell Market Key Industry Dynamics6. Human Embryonic Stem Cell Market Global Analysis7. Human Embryonic Stem Cell Market Revenue And Forecasts To 2027 Product Type8. Human Embryonic Stem Cell Market Revenue And Forecasts To 2027 Application9. Human Embryonic Stem Cell Market Revenue And Forecasts To 2027 End User10. Human Embryonic Stem Cell Market Revenue And Forecasts To 2027 Geographical Analysis

11. Human Embryonic Stem Cell Market Analysis And Forecasts To 2027 Industry Landscape12. Human Embryonic Stem Cell Market-Key Company Profiles13. Appendix

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

Read More About This Report Athttps://www.theinsightpartners.com/buy/TIPRE00005165/

Report Focus:

Extensive product offeringsCustomer research servicesRobust research methodologyComprehensive reportsLatest technological developmentsValue chain analysisPotential Cosmeceuticals Market opportunitiesGrowth dynamicsQuality assurancePost-sales supportRegular report updates

Key Questions Answered:

o How big will the market for Human Embryonic Stem Cell be in 2027?o What is the current CAGR of the Human Embryonic Stem Cell Market?o Which product is expected to have the highest market growth?o Which application should be used to win a large part of the market for Human Embryonic Stem Cell ?o Which region is likely to offer the most opportunities on the Human Embryonic Stem Cell Market?o Will the market competition change in the forecast period?o Who are the main players currently active in the global Human Embryonic Stem Cell Market?o How will the market situation change within the coming years?o What are the usual commercial tactics for players?o What is the growth perspective of the global Human Embryonic Stem Cell Market?

About us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact us: Call: +1-646-491-9876Email: [emailprotected]

More here:
Human Embryonic Stem Cell Market to Witness a Ravishing Growth with International Players BD, Takara Bio Inc., Geron, Thermo Fisher Scientific Inc.,...

Tip Sheet: HIV and COVID-19, antibody interactions, immune responses to colorectal cancer and how Fred Hutch is getting back to work – Fred Hutch News…

____________________________________________________________________COVID-19

Vaccinating the world: Two global experts explain what it will take to succeedDr. Larry Corey and Dr. John Mascola join Fred Hutch President and Director Dr. Tom Lynch to discuss the challenges and opportunities in accelerating development and distribution of COVID-19 vaccines for our integrated world in this webinar on Friday, June 5, 2020 at 11 am PST/ 2 pm EST.Media contact: Claire Hudson, crhudson@fredhutch.org

What happens when cancer patients get COVID-19?A large new study of cancer patients with COVID-19 clearly shows patients with active cancer or who suffer from additional comorbidities such as diabetes or heart disease have worse outcomes.Media contact: Claire Hudson, crhudson@fredhutch.org

When COVID-19 crosses paths with HIVResearchers at Fred Hutch are trying to assess whether HIV puts people at higher risk COVID-19 through a new epidemiological study of over 35,000 people living with HIV across the US. The study aims to identify risk factors for those with HIV who also had COVID-19 and understand if they are at risk of more severe infection. Media contact: Claire Hudson, crhudson@fredhutch.org

How Fred Hutch is using science to get back to doing scienceFred Hutch is tapping its decades of scientific expertise to move forward in finding ways to safely dial back up its employees on campus while supporting others working remotely. See steps being taken, plus a video of Fred Hutchs facilities director on how his team is managing during the pandemic.Media contact: Molly McElroy, mwmcelro@fredhutch.org

____________________________________________________________________

HIV

Injectable HIV drug prevents infectionsIn a real win for HIV prevention, an international trial of an injectable drug designed to prevent HIV showed those who received it had fewer new HIV infections than those who received the once-a-day HIV prevention pill Truvada.Media contact: Claire Hudson, crhudson@fredhutch.org

_____________________________________________________________________

Healthcare economics

NIH grant to fund new financial-toxicity interventionA new collaboration between Fred Hutch and the SWOG Cancer Research Network will road-test a program designed to curb financial toxicity related to cancer treatment. The intervention will give cancer patients access to proactive financial counseling and financial navigators as part of their treatment plan.Media contact: Claire Hudson, crhudson@fredhutch.org

_____________________________________________________________________

Precision medicine

Immune response in colorectal cancer: What helps, what hurts?A new $3.66 million grant from the National Cancer Institute will help Fred Hutch researchers, part of the Genetics and Epidemiology of Colorectal Cancer Consortium, better understand the bodys natural immune response to colorectal cancer and what, exactly, drives it.Media contact: Tom Kim, tomkim@fredhutch.org

$3.5M grant to develop safer treatment for inherited blood disordersDrs. Hans-Peter Kiem and Roland Walter will explore ways to precisely deliver powerful radioactive particles to blood and marrow cells while sparing other nonblood cells and tissues.Media contact: Molly McElroy, mwmcelro@fredhutch.org

_____________________________________________________________________

Pediatric Oncology

Cancers toll on the heart decades down the roadDr. Eric Chow and colleagues explore two key questions related to child cancer survivorship: Is there anything doctors can do during a childs treatment to protect their heart? And for adult survivors, what can we do to monitor and reduce the risk of heart disease?Media contact: Molly McElroy, mwmcelro@fredhutch.org

_____________________________________________________________________

Basic sciences

Studying the complex interactions between antibodies and viral targetsDr. Tal Einav was named a Damon Runyon Quantitative Biology Fellow, which supports cancer-related computation research. He will create maps that model how complex mixes of antibodies interact.Media contact: Molly McElroy, mwmcelro@fredhutch.org

_____________________________________________________________________

Other notable news

Dr. Hans-Peter Kiem elected vice president of American Society of Gene & Cell Therapy

Health equity trailblazers recognized

# # #

AtFred Hutchinson Cancer Research Center,home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutchs pioneering work inbone marrow transplantationled to the development ofimmunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nations first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Womens Health Initiative and the international headquarters of theHIV Vaccine Trials Network.

View original post here:
Tip Sheet: HIV and COVID-19, antibody interactions, immune responses to colorectal cancer and how Fred Hutch is getting back to work - Fred Hutch News...

SARS-CoV-2 can adversely affect cardiac cells and heart function – News-Medical.Net

A research group from Germany demonstrated a direct toxic effect of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on cardiac cells in their paper published on the bioRxiv* preprint server. The finding warrants an in-depth analysis of cardiac tissue in certain coronavirus disease (COVID-19) patients, as well as close monitoring for any direct cardiomyocyte injury.

COVID-19 pandemic has spread around the globe, putting billions of people into lockdown as health services try to cope with gravely ill individuals. Elderly and those with pre-existing medical conditions appear to be in jeopardy of serious disease outcomes.

Patients with underlying cardiovascular diseases present with an increased risk of death after SARS-CoV-2 infection. Moreover, clinical deterioration during COVID-19 is accompanied by left ventricular dysfunction in approximately 20% of patients, which is a striking number.

Nonetheless, it is not clear whether biomarkers of cardiac injury and long-term adverse effects on the cardiovascular system are caused directly by viral infection of the heart tissue, or they arise secondary to hypoxia (i.e., oxygen deprivation) and systemic inflammation during complicated COVID-19.

Previous research has hinted that human cardiomyocytes (heart cells) express the recognized SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2), most notably in patients with cardiovascular diseases, suggesting that they could be targeted by the novel coronavirus.

SARS-CoV-2 virus binding to ACE2 receptors on a human cell. Image Credit: Kateryna Kon / Shutterstock

This is why researchers from Frankfurt University, University Medical Center Hamburg-Eppendorf, German Center for Cardiovascular Research, Max Planck Institute Heart and Lung Research, Cardiopulmonary Institute, Fraunhofer Institute for Molecular Biology and Applied Ecology, German Centre for Infection Research, and several specialty clinics decided to investigate whether human cardiomyocytes are actually permissive for SARS-CoV-2 infection.

The researchers induced the infection by two control strains of SARS-CoV-2 (previously propagated in Caco-2 cell lines) in human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CM), as well as in two models of human cardiac tissue.

By using human cardiospheres (i.e., a cluster of endogenous heart stem cells that arises when they are cloned in suspension) generated by hiPS-cells, they aimed to determine whether SARS-CoV-2 infects cardiomyocytes in a three-dimensional tissue environment.

Finally, these scientists also addressed whether SARS-CoV-2 can infect human heart tissue by using living human cardiac tissue slices obtained from explanted hearts. All cytopathogenic effects were appraised visually 48 hours following the infection.

The study has shown that SARS-CoV-2 can readily infect human cardiomyocytes in culture, as well as in two different models of heart tissue. The infection was demonstrated by an assortment of readouts including the expression of intracellular viral RNA and its spike glycoprotein.

"Increasing concentrations of virus RNA are detected in supernatants of infected cardiomyocytes, which induced infections in CaCo-2 cell lines documenting productive infections", explain study authors.

The virus was further detected by in cells of the infected human heart slices by using electron microscopy, and it was also shown that it undergoes a full replication cycle. Of note, pro-apoptotic effects were also generated by SARS-CoV-2, which means it induces programmed cell death in cardiomyocytes.

In a nutshell, SARS-CoV-2 infection in this study was linked to cytotoxic changes and lower beating rate of heart cells in laboratory cultures and cardiospheres, suggesting a purported detrimental effect of the virus on the human heart.

"SARS-CoV-2 time-dependently affected beating frequency of cardiospheres with a profound inhibition at 5 days post-infection", further elucidate study authors. "At five days post-infection, cardiospheres showed a reduced size consistent with the induction of cell death," they add.

Although there was evidence that patients with COVID-19 had elevated cardiac injury biomarkers, as well as certain problems with left and right ventricular cardiac function, this is the first time a direct viral infection of cardiomyocytes by SARS-CoV-2 has been demonstrated convincingly.

"The used three-dimensional tissue models may serve as an experimental model for testing the effects of coronavirus infection and biology in the heart and developing therapeutic strategies," study authors explain implications of their research findings.

In any case, the significant adverse effects of SARS-CoV-2 on human cardiomyocytes as described in this study definitely warrants additional, continuous, and comprehensive monitoring of direct cardiac changes in COVID-19 patients.

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

See more here:
SARS-CoV-2 can adversely affect cardiac cells and heart function - News-Medical.Net

NAU scientist collaborating on vault-based vaccine to prevent and treat COVID-19 – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Jun 1 2020

C. Todd French, assistant professor of biology and leader of Northern Arizona University's new COVID-19 Testing Service Center (CTSC), is working with scientists at Vault Pharma, an emerging biotechnology company, to test candidate vaccines against the novel coronavirus. Through a multi-institutional public-private partnership linking the company with UCLA, NAU and the University of Nebraska-Lincoln, French is part of a collaborative team advancing a vaccine that has the potential to treat the virus in addition to protecting against it.

Vault Pharma creates genetically modified versions of vaults--naturally occurring nanoparticles found inside every cell of the human body--that can be bioengineered and used as drug delivery devices. So small that they are measured in nanometers (one nanometer equals one billionth of a meter), vaults were first discovered in 1986 by a lab group led by Vault Pharma co-founder Leonard H. Rome, distinguished professor of biological chemistry and associate director of the California NanoSystems Institute (CNSI) at UCLA. Vault Pharma is designing its vault vaccine with the Rome Lab and the research team led by Jeff F. Miller, UCLA's Fred Kavli Professor of NanoSystems Sciences and the director of CNSI.

Vaults are unique, hollow, natural protein nanoparticles, named for their barrel-like structure. They have tremendous potential as a vaccine delivery platform when loaded with vaccine antigens. I've been a proponent of the vault vaccine platform for a long time, and I'm excited that UCLA and Vault Pharma want to work with us at NAU."

C. Todd French, assistant professor of biology and leader of Northern Arizona University's new COVID-19 Testing Service Center (CTSC)

As with typical vaccines, the team's vault-based strategy is intended to stop infection before it starts by activating the antibodies in the immune system, which neutralize foreign microbes floating around in bodily fluids and tag them for elimination by immune cells. The researchers are choosing which coronavirus proteins to package inside vaults to stimulate the immune response.

Although it would not provide a frontline defense, the vault-based coronavirus vaccine in development is intended to be used against the disease after an initial vaccine has been developed and distributed, and could represent a step toward blocking the outbreak of a similar virus in the future.

The team at Vault Pharma has evidence suggesting that a vault-based vaccine could also work as a therapeutic. While the vault platform hasn't yet been tested in humans, proof-of-concept studies indicate that vaults themselves don't set off an immune attack but are readily internalized by multiple cells of the immune system.

French was recently recruited by NAU's Pathogen and Microbiome Institute from UCLA for his expertise. A veteran of Select Agent and high-containment pathogen science, French brings unique capabilities to PMI. The French Lab focuses on pathogen virulence mechanisms, pathogen ecology and developing new therapeutics.

"We established the CTSC at NAU to aid in the search for potential therapeutics that can inhibit the coronavirus in vitro. This summer, we will be bringing online the ability to test potential treatments and vaccines in COVID models, as well," French said.

Plans for manufacturing the vault-based vaccine are in progress. As the project moves toward trials in humans, production of vaccine-laden vaults will be scaled up at the University of Nebraska-Lincoln.

See the rest here:
NAU scientist collaborating on vault-based vaccine to prevent and treat COVID-19 - News-Medical.Net

The Genetics of Cancer Infographic – Technology Networks

InfographicJun 02, 2020| By Molly Campbell and Laura Elizabeth Lansdowne, Science Writers, Technology Networks.

Cancer is the term used to describe an incredibly complex group of diseases, caused by changes to the genes in one cell or a group of cells. These genetic alternations disrupt the normal functioning of the cell/s giving rise to several phenotypic changes or hallmarks that distinguish them from healthy cells in the body.

Download this infographic to discover:

Original post:
The Genetics of Cancer Infographic - Technology Networks

What can at-home genetic tests tell you about heart-related risks? – Harvard Health

Published: June, 2020

About 30 million Americans have used direct-to-consumer genetic tests such as 23andMe and Ancestry. While some are simply curious about their ethnic heritage, many pay extra to learn about their propensity for certain diseases and conditions. But can the results tell you anything useful about your odds of developing heart disease, the nation's leading killer?

When it comes to coronary artery disease by far the most common form of heart disease the answer is maybe, says Dr. Pradeep Natarajan, director of preventive cardiology at Harvard-affiliated Massachusetts General Hospital. "Genetics are just one aspect of a person's risk. Lifestyle habits such as smoking, diet, and exercise play a bigger role," he says.

Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.

Read more here:
What can at-home genetic tests tell you about heart-related risks? - Harvard Health

Genetic features pave way for targeted BPDCN therapies – Dermatology Times

Researchers are learning more about genetic aberrations common in the rare but clinically aggressive hematological cancer blastic plasmacytoid dendritic cell neoplasm. There is one targeted therapy approved by the U.S. Food and Drug Administration: Elzonris (tagraxofusp-erzs, Stemline). However, more treatment options are needed to improve the cancers clinical outcome, according to a review published May 2020 in Critical Reviews Oncology/Hematology.1

Dermatologists might be the first providers to encounter patients with blastic plasmacytoid dendritic cell neoplasm because more than 70% of these patients have cutaneous lesions. Those lesions often are asymptomatic and vary in size. The skin lesions tend to have nodules, plaques or bruise-like areas, a brown to violet color and might be solitary or multifocal, according to the authors.

Blastic plasmacytoid dendritic cell neoplasm often originates from type 2 myeloid-derived resting plasmacytoid dendritic cell precursors. Recent research suggests providers can diagnose the cancer when patients express at least four of five plasmacytoid dendritic cell specific markers, CD4, CD56, CD123, TCL1 and BDCA-2, without expressing myeloid, T-cell or B-cell lineage markers.

Commonly, [blastic plasmacytoid dendritic cell neoplasm] is characterized by high CD123 expression, aberrant NF-B [nuclear factor-B] activation, dependence on TCF4-/BRD4-network, and deregulated cholesterol metabolism, they wrote.

Despite advancing knowledge about the cancer type, patients median overall survival remains at 12 to 14 months, according to the paper. Conventional treatment approaches include chemotherapy, radiotherapy and ultimately hematopoietic stem cell transplantation. The challenges with conventional therapies are while blastic plasmacytoid dendritic cell neoplasm is sensitive to some chemotherapy regimens, patient relapse is high at more than 60%. And many patients with blastic plasmacytoid dendritic cell neoplasm are too old or frail to have intensive chemotherapy or hematopoietic stem cell transplantation, according to the authors.

Recently, the most attractive agent for [blastic plasmacytoid dendritic cell neoplasm] is tagraxofusp, which is composed of the catalytic and translocation domains of diphtheria toxin (DT) fused to interleukin-3 (IL-3), the authors wrote.

Blastic plasmacytoid dendritic cell neoplasm cells overexpress interleukin-3 receptor subunit alpha (IL3RA, also called CD123). Elzonris, or tagraxofusp-erzs, is a CD123-directed cytotoxin given intravenously, which is used to treat blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients 2 years and older.

Researchers reported in a study of 47 blastic plasmacytoid dendritic cell neoplasm patients published in 2019 in the New England Journal of Medicine that tagraxofusp led to clinical responses in untreated and relapsed patients.2 The overall response rate with tagraxofusp was 90% and the primary outcome of complete response and clinical complete response was 72% among the previously untreated patients. Overall response was 67% in the previously treated patients. Serious adverse events including capillary leak syndrome, hepatic dysfunction and thrombocytopenia were common, according to the NEJM paper.

More targeted therapies are needed to treat blastic plasmacytoid dendritic cell neoplasm, but many potential therapeutic agents are not advancing to clinical trials, according to authors of the paper in Critical Reviews Oncology/Hematology.

Common blastic plasmacytoid dendritic cell neoplasm characteristics are genetically heterogeneous and provide valuable drug targets, according to the authors.

Apart from aberrant activation of NF-B signaling pathway, which is highly dependent on TCF4- and BRD4- transcriptional networks, cholesterol metabolism deregulation and CD123 expression, defects of DNA damage repair and mitosis are new, potential common features of the cancer. Corresponding therapies might be promising, the authors wrote.

Venetoclax, anti-CD123 CAR-T, XmAb14045 and IMGN632 are in clinical trials for blastic plasmacytoid dendritic cell neoplasm. But the authors noted that bortezomib, lenalidomide, 5-aza and pralatrexate could easily be pushed to the front line of the cancers treatment.

Disclosures:

The authors report no relevant disclosures.

References:

1. Zhang X, Sun J, Yang M, Wang L, Jin J. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm. Crit Rev Oncol Hematol. 2020 May;149:102928.2. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019;380(17):1628-1637.

Read more:
Genetic features pave way for targeted BPDCN therapies - Dermatology Times

New physicians coming to the northeast – northeastNOW

The town of Tisdale is also set to welcome a new physician.

Dr. Omotayo Abiara will provide services out of the Northeast Medical Clinic in Tisdale, starting Monday, June 15.

Dr. Abiara is from Nigeria, and earned her Bachelor of Medicine, Bachelor of Surgery at the University in Ibadan, Nigeria.

She also holds a Masters Degree in clinical embryology from the University of Leeds, United Kingdom.

The SHA said in its news release Dr. Abiara has more than 10 years of experience as a family physician and general medical practitioner, and has a special interest in womens health.

Patients looking for a family physician can call Northeast Medical Clinic at 306-873-4561 to have their patient files transferred, and to make an appointment.

Editors note: this article was amended to correct the phone number initially given for the Porcupine Medical Clinic.

cam.lee@jpbg.ca

On Twitter: @camlee1974

Read the original here:
New physicians coming to the northeast - northeastNOW